- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07613593
INCLUDE-CKD: INCLUsive Digital carE for Chronic Kidney Disease (INCLUDE-CKD)
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
- Retrospective: ~450-500 existing users + matched controls(24 months data).
- Comparison with entire WKC CKD population
- Prospective: ~500-550 new users + matched controls (6 months).
- Exploratory: ~500 dialysis or pre transplant MyRenalCare users (no matched controls).
- Qualitative: 15-25 patients + 10-15 staff.
Beschrijving
Inclusion Criteria:
5.1.1 Inclusion criteria - MyRenalCare users (retrospective and prospective cohorts)
Adults will be eligible for inclusion in the MyRenalCare cohorts if they meet all of the following:
- Aged 18 years or over.
- Under the care of the Wessex Kidney Centre
- Registered with, or offered and subsequently enrolled onto, the MyRenalCare platform during the defined retrospective or prospective periods.
- Able to understand study information and, where applicable, provide informed consent for use of their data for research purposes.
Specific CKD stage definitions and thresholds (e.g. based on eGFR, albuminuria or uPCR) will be documented in the study manual to ensure consistent application.
5.1.2 Inclusion criteria - matched usual care controls
Adults will be eligible for inclusion in the matched control cohorts if they meet all of the following:
- Aged 18 years or over.
- Under the care of the Wessex Kidney Centre for chronic kidney disease.
- Not registered with or using MyRenalCare at any point during the relevant observation period.
- Have sufficient clinical and administrative data available in the renal electronic patient record to enable matching and outcome assessment.
Controls will be identified retrospectively from the renal electronic patient record and matched to MyRenalCare users using a predefined matching strategy.
5.1.3 Inclusion criteria - qualitative interview participants (patients and staff)
Patients will be eligible to take part in the qualitative interview component if they meet all of the following:
- Aged 18 years or over.
- Currently using, or recently offered, the MyRenalCare platform as part of their CKD care at the Wessex Kidney Centre.
- Able to understand spoken and written English to the extent required for participation in an interview.
- Able and willing to provide written informed consent for participation in a recorded interview.
- Belong to a demographic or clinical subgroup of interest for the study (e.g. varying age, ethnicity, CKD stage, or digital engagement level), as part of purposive sampling to support diversity and equity analysis.
Clinical staff will be eligible if they meet all of the following:
- Employed by PHU or working in direct partnership with the Wessex Kidney Centre.
- Directly involved in the care of patients with chronic kidney disease and/or in the implementation or support of MyRenalCare.
- Able and willing to provide informed consent for a recorded interview.
- Able to reflect on experiences and observations relevant to the delivery, uptake, or equity implications of digital health in CKD.
Exclusion Criteria:
- Patients with acute kidney injury without established chronic kidney disease.
- Patients with a very limited life expectancy where participation in routine digital monitoring is not appropriate, as judged by the clinical team.
- Patients who have previously indicated that they do not wish their routinely collected clinical data to be used for research where such opt-out applies to this study.
- Patients who are unable to be identified reliably in the available data sources (for example, inconsistent or missing key identifiers).
- Any other situation where, in the opinion of the responsible clinician, participation in the study processes (including data use) would be inappropriate or unduly burdensome.
- Clinical staff who are not directly involved in the care of patients with chronic kidney disease or in the implementation of the MyRenalCare platform.
- Staff members currently on extended leave or unable to participate during the data collection period.
- Individuals who do not wish to have their views included in recorded interview transcripts or are unable to provide informed consent for participation.
- Any situation where, in the opinion of the study team or the individual's manager, participation would be inappropriate or burdensome due to role, availability, or conflict of interest.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Existing MyRenalCare users (retrospective cohort)
Adults who were already registered and actively using MyRenalCare at the start of the retrospective observation period.
Data will be collected retrospectively from their routine use of the platform.
|
Study is non-interventional.
Andere namen:
|
|
New MyRenalCare users (prospective cohort)
Adults who are newly offered and enroll onto MyRenalCare during the defined recruitment window.
Participants will use the platform as part of routine care, and their engagement will be prospectively monitored.
|
Study is non-interventional.
Andere namen:
|
|
Matched usual care controls
Adults with CKD receiving standard care at the Wessex Kidney Centre who are not enrolled onto MyRenalCare.
These participants receive usual clinical care without access to the MyRenalCare platform.
|
Study is non-interventional.
Andere namen:
|
|
Patients and staff participating in qualitative interviews (qualitative cohort)
A subset of MyRenalCare users (both retrospective and prospective) and clinical staff involved in their care who are invited to take part in interviews about their experiences with MyRenalCare.
|
Study is non-interventional.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Primary
Tijdsspanne: 12 months
|
Outcome measure 1: Number and proportion of MyRenalCare users by age, sex, ethnicity and Index of Multiple Deprivation quintile, compared with the CKD population under Wessex Kidney Centre care.
Prevalence ratios will also be calculated.
|
12 months
|
|
Primary
Tijdsspanne: 12-months
|
Outcome measure 2: Composite digital adherence score (0-100) for MyRenalCare users, combining log-in frequency, completeness of blood pressure and symptom entries, use of secure messaging and duration of sustained use. Analyses stratified by age, sex, ethnicity and deprivation. |
12-months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Secondary
Tijdsspanne: 12-months
|
Outcome measure1: Number of unplanned and planned hospital admissions for MyRenalCare users compared with matched usual-care controls.
|
12-months
|
|
Secondary
Tijdsspanne: 12-months
|
Outcome measure 2: Number of outpatient visits (renal and non-renal) for MyRenalCare users compared with matched usual-care controls.
|
12-months
|
|
Secondary
Tijdsspanne: 12-months
|
Outcome measure 3: CKD progression, measured by change in eGFR, movement between CKD stages, and initiation of kidney replacement therapy for MyRenalCare users versus matched controls.
|
12-months
|
|
Secondary
Tijdsspanne: 12-months
|
Outcome measure 4: NHS healthcare costs per patient-year for MyRenalCare users compared with matched usual-care controls, including inpatient, outpatient, emergency and relevant community or virtual care contacts.
|
12-months
|
|
Secondary
Tijdsspanne: 12-months
|
Outcome measure 5: Estimated patient travel-related CO₂ emissions for renal care appointments for MyRenalCare users versus matched usual-care controls, based on travel distance and mode.
|
12-months
|
|
Secondary
Tijdsspanne: 12-months
|
Outcome measure 6: Themes from qualitative interviews with patients and staff on MyRenalCare usability, support needs, barriers and facilitators to digital engagement.
|
12-months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Pathologische processen
- Mannelijke urogenitale ziekten
- Nier Ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Chronische ziekte
- Ziekte attributen
- Nierinsufficiëntie
- Pathologische aandoeningen, tekenen en symptomen
- Nierinsufficiëntie, chronisch
Andere studie-ID-nummers
- PHU/2024/28
- NIHR510403 (Andere identificatie: NIHR - 2025/400 i4i FAST Commissioned)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Chronische nierziekte
-
Zhen LiAanmelden op uitnodigingGelijktijdige pancreas-kidney transplantatieChina
-
Third Affiliated Hospital, Sun Yat-Sen UniversityActief, niet wervendAcute-on-chronic leverfalen (ACLF)China
-
CHU de ReimsNog niet aan het wervenVloeistofresponsiviteit in de vroege post-kidney transplantatieperiodeFrankrijk
-
Chung Shan Medical UniversityNational Science and Technology Council, TaiwanNog niet aan het wervenObesitas Type 2 Diabetes Mellitus | Metabole disfunctie-geassocieerde steatotische leverziekte | Cardiovasculair-kidney-metabool syndroomTaiwan
-
Yaqrit LtdKing's College Hospital NHS Trust; University College, London; Royal Free Hospital... en andere medewerkersNog niet aan het wervenLevercirrose | Acute-on-chronic leverfalen (ACLF)
-
Camille N. Kotton, MDKamada, Ltd.; University of Texas Southwestern Medical CenterWervingCytomegalovirus | Niertransplantatie; complicaties | Orgaan transplantatie | Levertransplantatie complicaties | Gelijktijdige lever-kidney transplantatie; ComplicatiesVerenigde Staten
-
University Hospital, Basel, SwitzerlandNog niet aan het wervenCardiovasculair-kidney-metabool syndroom | Cradiovascular-Kidney-Liver-Metabolic (CKLM) syndroomZwitserland
-
Institute of Liver and Biliary Sciences, IndiaNog niet aan het wervenAcute-on-chronic leverfalen (ACLF)
-
Nanjing Medical UniversityNog niet aan het wervenCardiovasculair-kidney-metabool syndroom
-
Institute of Liver and Biliary Sciences, IndiaNog niet aan het wervenAcute-on-chronic leverfalen (ACLF)
Klinische onderzoeken op Non-Interventional Study
-
Hospices Civils de LyonVoltooidTotale heupartroplastiek voor artroseFrankrijk
-
Saglik Bilimleri UniversitesiVoltooidBepaling van het effect van op case management gebaseerde elektronische foetale monitoringtraining gegeven aan studenten van verloskundigen op EFM-monitoring van zelfeffectiviteitKalkoen
-
Collagen MatrixWervingPost-Market Clinical Investigation Plan- Collageen Dural Regeneration Matrix (Duramatrix-onlay Plus)Reparatie van dura materVerenigde Staten
-
University of MichiganVoltooid
-
University of MichiganVoltooid
-
Tempus AIWervingAcute myeloïde leukemie (AML) | Folliculair lymfoom (FL)Verenigde Staten
-
Radicle ScienceVoltooidCognitieve functieVerenigde Staten
-
Cairo UniversityNog niet aan het wervenSlaapkwaliteit, fysieke fitheid en body mass index
-
M2 IngredientsWervingCognitieve achteruitgangVerenigde Staten
-
Apple Inc.Stanford UniversityVoltooidBoezemfibrilleren | Aritmieën, hart | Atriale flutterVerenigde Staten